NASDAQ:ATRA Atara Biotherapeutics Q2 2026 Earnings Report $9.69 -0.02 (-0.21%) As of 09/18/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Atara Biotherapeutics EPS ResultsActual EPS-$0.32Consensus EPS -$0.32Beat/MissMissed by -$0.01One Year Ago EPSN/AAtara Biotherapeutics Revenue ResultsActual Revenue$0.63 millionExpected Revenue$0.55 millionBeat/MissBeat by +$80.00 thousandYoY Revenue GrowthN/AAtara Biotherapeutics Announcement DetailsQuarterQ2 2026Date8/12/2026TimeAfter Market ClosesConference Call DateWednesday, August 12, 2026Conference Call Time7:00AM ETUpcoming EarningsAtara Biotherapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Atara Biotherapeutics Earnings HeadlinesAtara Biotherapeutics (NASDAQ:ATRA) Share Price Passes Above 50-Day Moving Average - What's Next?September 12, 2026 | americanbankingnews.comAtara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational ProgressAugust 12, 2026 | finance.yahoo.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.September 19 at 1:00 AM | Paradigm Press (Ad)Atara Biotherapeutics Announces $15 Million Registered Direct OfferingJuly 7, 2026 | businesswire.comQuetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic LeukemiaJune 11, 2026 | globenewswire.comAtara Biotherapeutics Inc (ATRA)May 31, 2026 | investing.comSee More Atara Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atara Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atara Biotherapeutics and other key companies, straight to your email. Email Address About Atara BiotherapeuticsAtara Biotherapeutics (NASDAQ:ATRA) is a biotechnology company focused on developing allogeneic T-cell immunotherapies for cancer, autoimmune diseases and other serious conditions. Its platform uses T cells derived from healthy donors and engineered or selected to recognize disease-associated targets, with the goal of creating “off-the-shelf” treatments that can be administered without collecting and manufacturing a patient’s own cells. The company’s leading product is tabelecleucel, marketed as Ebvallo, an allogeneic T-cell therapy designed to target Epstein-Barr virus-positive cells. Ebvallo has been approved in the United States and European Union for certain patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease, a rare and potentially life-threatening complication that can occur after organ or stem-cell transplantation. Atara has also investigated its platform in multiple sclerosis and other immune-mediated diseases, as well as additional oncology indications. Founded in 2012, Atara has operated internationally through clinical development, regulatory and commercial activities in North America and Europe. The company has collaborated with external partners to support the development, manufacturing and commercialization of its therapies. Pascal Touchon has served as Atara’s president and chief executive officer, although leadership and corporate arrangements may change as the company’s business develops.View Atara Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
